The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
Subscribe To Our Newsletter & Stay Updated
